Lansoprazole Alone or in Combination With Gefitinib Shows Antitumor Activity Against Non-small Cell Lung Cancer A549 Cells in vitro and in vivo

Lansoprazole (Lpz) is an FDA-approved proton pump inhibitor (PPI) drug for the therapy of acid-related diseases. Aiming to explore the new application of old drugs, we recently investigated the antitumor effect of Lpz. We demonstrated that the PPI Lpz played a tumor suppressive role in non-small cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xiaoxia, Zhang, Ning, Huang, Yingying, Dou, Xiaojing, Peng, Xiaolin, Wang, Wei, Zhang, Zhe, Wang, Ran, Qiu, Yuling, Jin, Meihua, Kong, Dexin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093516/
https://www.ncbi.nlm.nih.gov/pubmed/33959611
http://dx.doi.org/10.3389/fcell.2021.655559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093516/
https://www.ncbi.nlm.nih.gov/pubmed/33959611
http://dx.doi.org/10.3389/fcell.2021.655559

Ejemplares similares